{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:59:42Z","timestamp":1789851582728,"version":"4.0.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Timely outpatient treatment for COVID-19 reduces the risk of hospitalization and death in high-risk patients. However, large racial and ethnic inequities in treatment have been observed across the US. The relative contributions of care mechanisms that create barriers (eg, access to home tests or telemedicine) are unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the relative contribution of structural and encounter-level factors associated with racial and ethnic disparities in oral antiviral prescribing for COVID-19.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this cross-sectional study using electronic health record data from a large northeastern health care system, medication order receipt was estimated across racial and ethnic minority groups. The sample comprised patients aged 18 years or older with documented positive COVID-19 test results from January 1, 2022, through January 31, 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Race and ethnicity as recorded in patient electronic health records.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was prescription orders of nirmatrelvir\/ritonavir or molnupiravir within 7 days of a positive COVID-19 test result. Nested linear probability models were used, adjusting for clinical characteristics (age, sex, comorbidities, and contraindications), public health determinants (vaccination, insurance, and language), time fixed effects, and encounter-level characteristics (virtual care, diagnostic test type, and clinic site). The relative contribution of these factors to racial and ethnic prescription disparity was then partitioned.<\/jats:p><\/jats:sec>Results<\/jats:title>The sample consisted of 201\u202f964 patients with positive COVID-19 test results (mean [SD] age, 54.0 [18.2] years; 64.6% female; 0.1% identified as American Indian or Alaska Native, 3.7% as Black, 6.5% as Hispanic or Latino, 79.0% as White, 1.1% as other, and 4.7% as unknown race and ethnicity). Most were commercially insured (66.4%). Unadjusted prescription rates were 10.8 percentage points (95% CI, 9.7-11.8 percentage points) lower for Black compared with White patients and 9.8 percentage points (95% CI, 9.0-10.6 percentage points) lower for Latino patients. Black and Latino patients were less likely than White patients to be diagnosed with in-clinic antigen tests (\u22128.4 percentage points [95% CI, \u22129.2 to \u22127.5 percentage points] and \u22127.7 percentage points [95% CI, \u22128.3 to \u22127.0 percentage points], respectively), by home antigen tests (\u221210.3 percentage points [95% CI, \u221211.5 to \u22129.2 percentage points] and \u221214.1 percentage points [95% CI, \u221214.9 to \u221213.2 percentage points], respectively), or to have received care virtually (\u221216.2 percentage points [95% CI, \u221217.3 to \u221215.0 percentage points] and \u221218.4 percentage points [95% CI, \u221219.3 to \u221217.5 percentage points], respectively). Observable covariates fully accounted for the unadjusted prescription differences, with 53% of the racial and ethnic prescription gap for Black patients and 39% for Latino patients explained by encounter-level factors.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cross-sectional study found that racial and ethnic disparities in COVID-19 treatment are substantial and partially explainable by encounter-level factors, particularly differences in diagnostic test type, virtual care access, and site of care. These findings suggest that targeted interventions, including expanding rapid test access and virtual care, may improve equity in outpatient COVID-19 treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.18459","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:00:52Z","timestamp":1751382052000},"page":"e2518459","source":"Crossref","is-referenced-by-count":5,"title":["Racial Inequities and Access to COVID-19 Treatment"],"prefix":"10.1001","volume":"8","author":[{"given":"Rebecca","family":"Bromley-Dulfano","sequence":"first","affiliation":[{"name":"Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Barnett","sequence":"additional","affiliation":[{"name":"Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"15","key":"zoi250575r2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250575r3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250575r6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis.","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"43","key":"zoi250575r7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","article-title":"Racial and ethnic disparities in outpatient treatment of COVID-19\u2013United States, January-July 2022.","volume":"71","author":"Boehmer","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi250575r9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s11606-022-07844-3","article-title":"Early racial and ethnic disparities in the prescription of nirmatrelvir for COVID-19.","volume":"38","author":"Tarabichi","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"24","key":"zoi250575r10","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2020.8598","article-title":"COVID-19 and racial\/ethnic disparities.","volume":"323","author":"Webb Hooper","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"zoi250575r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5044","article-title":"Clinical risk and outpatient therapy utilization for COVID-19 in the Medicare population.","volume":"5","author":"Wilcock","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"6","key":"zoi250575r12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2023.12945","article-title":"Monoclonal antibody and oral antiviral treatment of SARS-CoV-2 infection in US nursing homes.","volume":"330","author":"McGarry","year":"2023","journal-title":"JAMA"},{"issue":"25","key":"zoi250575r13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.15585\/mmwr.mm7125e1","article-title":"Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability\u2013United States, December 23, 2021-May 21, 2022.","volume":"71","author":"Gold","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi250575r14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1377\/hlthaff.2021.01394","article-title":"Systemic and structural racism: definitions, examples, health damages, and approaches to dismantling.","volume":"41","author":"Braveman","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"43","key":"zoi250575r15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.15585\/mmwr.mm7143a3","article-title":"Notes from the field: dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability\u2013United States, December 23, 2021-August 28, 2022.","volume":"71","author":"Sullivan","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi250575r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.0131","article-title":"Racial and ethnic differences in telemedicine use.","volume":"5","author":"Marcondes","year":"2024","journal-title":"JAMA Health Forum"},{"key":"zoi250575r19","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00648","article-title":"comorbidity: An R package for computing comorbidity scores.","author":"Gasparini","journal-title":"J Open Source Softw"},{"issue":"2","key":"zoi250575r24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1086\/683668","article-title":"When do covariates matter? and which ones, and how much?","volume":"34","author":"Gelbach","year":"2016","journal-title":"J Labor Econ"},{"key":"zoi250575r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metip.2021.100075","article-title":"Omitted variable bias: a threat to estimating causal relationships.","volume":"5","author":"Wilms","year":"2021","journal-title":"Methods Psychol"},{"issue":"2","key":"zoi250575r26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/oby.23608","article-title":"Explaining obesity disparities by urbanicity, 2006 to 2016: A decomposition analysis.","volume":"31","author":"Zang","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"zoi250575r27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1198\/jbes.2010.07136","article-title":"Robust inference with multiway clustering.","volume":"29","author":"Cameron","year":"2011","journal-title":"J Bus Econ Stat"},{"key":"zoi250575r1","unstructured":"Therapeutic management of nonhospitalized adults with COVID-19. 2023. Accessed October 23, 2023. https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management-of-adults\/nonhospitalized-adults--therapeutic-management\/"},{"key":"zoi250575r4","unstructured":"Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. US Food and Drug Administration. December 22, 2021. Accessed May 31, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"},{"key":"zoi250575r5","unstructured":"Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. US Food and Drug Administration. December 23, 2021. Accessed May 31, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"zoi250575r8","unstructured":"COVID-19 antivirals utilization: geographic and demographic patterns of treatment in 2022. Office of the Assistant Secretary for Planning and Evaluation. December 23, 2022. Accessed February 23, 2024. https:\/\/aspe.hhs.gov\/reports\/covid-19-antivirals-utilization"},{"key":"zoi250575r17","unstructured":"Mass General Brigham\u2019s fight against racism and for health equity. Mass General Brigham. Accessed October 8, 2024. https:\/\/www.massgeneralbrigham.org\/en\/about\/newsroom\/articles\/mass-general-brighams-fight-against-racism-and-health-equity"},{"key":"zoi250575r18","unstructured":"McNemar E. Mass General hits health equality via demographic data collection. TechTarget. June 25, 2021. Accessed March 6, 2025. https:\/\/www.techtarget.com\/healthtechanalytics\/news\/366591166\/Mass-General-Hits-Health-Equality-via-Demographic-Data-Collection"},{"key":"zoi250575r20","unstructured":"Implementation notice: requirement for race-neutral eGFR formulas in effect. United Network for Organ Sharing. July 27, 2022. Accessed October 8, 2024. https:\/\/unos.org\/news\/implementation-notice-race-neutral-egfr-formulas\/"},{"key":"zoi250575r21","unstructured":"Howard? J. Bias cut. Brigham and Women\u2019s Hospital. October 13, 2021. Accessed March 6, 2025. https:\/\/magazine.brighamandwomens.org\/features\/bias-cut"},{"key":"zoi250575r22","unstructured":"Fact sheet for healthcare providers EUA for Paxlovid. US Food and Drug Administration. June 21, 2021. Accessed June 3, 2024. https:\/\/www.fda.gov\/media\/155050\/"},{"key":"zoi250575r23","unstructured":"Fact sheet for healthcare providers: emergency use authorization for Lagevrio. US Food and Drug Administration. December 23, 2021. Accessed June 3, 2024. https:\/\/www.fda.gov\/media\/155054\/download"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835844\/bromleydulfano_2025_oi_250575_1750791785.35371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:00:56Z","timestamp":1751382056000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18459","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}